Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
A M Milan, A T Hughes, A S Davison, M Khedr, J Rovensky, E E Psarelli, T F Cox, N P Rhodes, J A Gallagher, L R Ranganath, A M Milan, A T Hughes, A S Davison, M Khedr, J Rovensky, E E Psarelli, T F Cox, N P Rhodes, J A Gallagher, L R Ranganath
Abstract
Nitisinone decreases homogentisic acid (HGA) in Alkaptonuria (AKU) by inhibiting the tyrosine metabolic pathway in humans. The effect of different daily doses of nitisinone on circulating and 24 h urinary excretion of phenylalanine (PA), tyrosine (TYR), hydroxyphenylpyruvate (HPPA), hydroxyphenyllactate (HPLA) and HGA in patients with AKU was studied over a four week period. Forty AKU patients, randomised into five groups of eight patients, received doses of 1, 2, 4 or 8 mg of nitisinone daily, or no drug (control). Metabolites were analysed by tandem mass spectrometry in 24 h urine and serum samples collected before and after nitisinone. Serum metabolites were corrected for total body water and the sum of 24 hr urine plus total body water metabolites of PA, TYR, HPPA, HPLA and HGA were determined. Body weight and urine urea were used to check on stability of diet and metabolism over the 4 weeks of study. The sum of quantities of urine metabolites (PA, TYR, HPPA, HPLA and HGA) were similar pre- and post-nitisinone. The sum of total body water metabolites were significantly higher post-nitisinone (p < 0.0001) at all doses. Similarly, combined 24 hr urine:total body water ratios for all analytes were significantly higher post-nitisinone, compared with pre-nitisinone baseline for all doses (p = 0.0002 - p < 0.0001). Significantly higher concentrations of metabolites from the tyrosine metabolic pathway were observed in a dose dependant manner following treatment with nitisinone and we speculate that, for the first time, experimental evidence of the metabolite pool that would otherwise be directed towards pigment formation, has been unmasked.
Trial registration: ClinicalTrials.gov NCT01828463.
Conflict of interest statement
Milan, Hughes, Davison, Khedr, Rovensky, Psarelli, Cox, Rhodes, Gallagher and Ranganath report that they have no competing interests (financial or non-financial).
Figures
References
- La DBN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alcaptonuria. J Biol Chem. 1958;230:251–60.
- O’Brien WM, La Du BN, Bunim JJ. Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: review of world literature (1584–1962) Am J Med. 1963;34:813–38. doi: 10.1016/0002-9343(63)90089-5.
- Mullan A, Cocker D, Taylor G, Millar C, Ranganath L. Fatal oxidative haemolysis and methaemoglobinaemia in a patient with alkaptonuria and acute kidney injury. Clin Kidney J. 2015;8:109–112. doi: 10.1093/ckj/sfu121.
- Davison AS, Milan AM, Gallagher JA, Ranganath LR. Acute fatal metabolic complications in alkaptonuria. JIMD. 2016;39:203–210.
- Zannoni VG, Lomtevas N, Goldfinger S. Oxidation of homogentisic acid to ochronotic pigment in connective tissue. Biochim Biophys Acta. 1969;177:94–105. doi: 10.1016/0304-4165(69)90068-3.
- Taylor AM, et al. The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheumatol. 2011;63:3887–3896. doi: 10.1002/art.30606.
- Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria. J Clin Pathol. 2013;66:367–73. doi: 10.1136/jclinpath-2012-200877.
- Ranganath LR, Cox T. Natural History of Alkaptonuria Revisited: analysis based on scoring systems. JIMD. 2011;34:1141–51.
- Phornphutkul C, et al. Natural history of Alkaptonuria. N Engl J Med. 2002;347:2111–21. doi: 10.1056/NEJMoa021736.
- Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strndvik B. Treatment of hereditary tyrosinaemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340:813–17. doi: 10.1016/0140-6736(92)92685-9.
- McKiernan PJ. Nitisinone for the treatment of hereditary tyrosinemia type I. Expert Opinion on Orphan. Drugs. 2013;1:491–497.
- Preston AJ, et al. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis. 2014;73:284–9. doi: 10.1136/annrheumdis-2012-202878.
- Keenan CM, Preston AJ. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice. JIMD Rep. 2015;24:45–50.
- Ranganath LR, et al. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ann Rheum Dis. 2016;75:362–7. doi: 10.1136/annrheumdis-2014-206033.
- Introne WJ, et al. A 3-year randomised therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab. 2011;103:307–14. doi: 10.1016/j.ymgme.2011.04.016.
- Hughes AT, et al. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry. Ann Clin Biochem. 2015;52:597–605. doi: 10.1177/0004563215571969.
- Bory C, Boulieu R, Chantin C, Mathieu M. Homogentisic acid determined in biological fluids by HPLC. Clin Chem. 1989;35:321–2.
- Hughes AT, et al. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;15:106–112. doi: 10.1016/j.jchromb.2014.06.002.
- Alam SQ, Rogers QR, Harper AE. Effect of tyrosine and threonine on free amino acids in plasma, liver, muscle and the eye in the rat. J Nutr. 1966;89:97–105. doi: 10.1093/jn/89.1.97.
- Madsen BW, Everett AW, Sparrow MP, Fowkes ND. Linear kinetic model to estimate protein synthesis after (14C)Tyrosine infusion in dogs. FEBS Letts. 1977;79:313–316. doi: 10.1016/0014-5793(77)80810-7.
- Deurenberg P, Wolde-Gebriel Z, Schouten FJM. Validity of Predicted Total Body Water and Extracellular Water Using Multifrequency Bioelectrical Impedance in an Ethiopian Population. Ann Nutr Metab. 1995;39:234–241. doi: 10.1159/000177868.
- Hegedus ZL. The probable involvement of soluble and deposited melanins, their intermediates and the reactive oxygen side-products in human diseases and aging. Toxicology. 2000;145:85–101. doi: 10.1016/S0300-483X(00)00157-8.
- Taylor, A. M. et al. Raman spectroscopy identifies differences in ochronotic and non-ochronotic cartilage: a potential novel technique for monitoring ochronosis. Osteoarthritis Cartilage, 10.1016/j.joca.2019.04.012 (Epub ahead of print) (2019).
- Tokuhara H, Shukuya K, Tanaka M, Sogabe K, Ejima Y, Hosokawa S, Ohsaki H, Morinishi T, Hirakawa E, Yatomi Y, Shimosawa T. Absorbance measurements of oxidation of homogentisic acid accelerated by the addition of alkaline solutions with sodium hypochlorite pentahydrate. Sci Rep. 2018;8:11364. doi: 10.1038/s41598-018-29769-w.
- Wolff JA, et al. Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatric Res. 1989;26:140–144. doi: 10.1203/00006450-198908000-00015.
- Lustberg TJ, Schulman JD, Seegmuller JE. Decreased binding of (14)C-homogentisic acid induced by ascorbic acid in connective tissues of rats with experimental alkaptonuria. Nature. 1970;228:770–771. doi: 10.1038/228770a0.
- Braconi D, et al. Evaluation of anti-oxidant treatment in an in vitro model of alkaptonuric ochronisis. Rheum. 2010;49:1975–1983. doi: 10.1093/rheumatology/keq175.
- Braconi D, et al. Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J Inherit Metab Dis. 2011;34:1163–1176. doi: 10.1007/s10545-011-9377-6.
- Millucci Lia, Bernardini Giulia, Spreafico Adriano, Orlandini Maurizio, Braconi Daniela, Laschi Marcella, Geminiani Michela, Lupetti Pietro, Giorgetti Giovanna, Viti Cecilia, Frediani Bruno, Marzocchi Barbara, Santucci Annalisa. Histological and Ultrastructural Characterization of Alkaptonuric Tissues. Calcified Tissue International. 2017;101(1):50–64. doi: 10.1007/s00223-017-0260-9.
- Braconi Daniela, Millucci Lia, Bernini Andrea, Spiga Ottavia, Lupetti Pietro, Marzocchi Barbara, Niccolai Neri, Bernardini Giulia, Santucci Annalisa. Homogentisic acid induces aggregation and fibrillation of amyloidogenic proteins. Biochimica et Biophysica Acta (BBA) - General Subjects. 2017;1861(2):135–146. doi: 10.1016/j.bbagen.2016.11.026.
- Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria—a review of surgical and autopsy pathology. Histopath. 2008;53:503–12.
Source: PubMed